Venthera, Inc.
BridgeBio is dedicated to designing transformative medicines for patients with genetic diseases by bringing science and finance together. They focus on discovering novel genetic disease targets, creating medicines with industry research capabilities, testing drugs through a global development footprint, and delivering products to patients via commercial infrastructures. Their mission is to help patients suffering from genetic diseases by developing breakthrough medicines rapidly and safely.
Industries
Venthera, Inc.
Products
Encaleret
Investigational orally administered small-molecule negative allosteric modulator of the calcium-sensing receptor being developed to restore mineral homeostasis in disorders characterized by CASR gain-of-function (including ADH1); being evaluated in global Phase 3 studies.
BBP-418
Investigational oral small molecule intended to increase glycosylation of alpha-dystroglycan by saturating partially functional FKRP enzyme activity, developed for limb-girdle muscular dystrophy type 2I/R9; in Phase 3 development.
Low-dose infigratinib (achondroplasia program)
Oral small-molecule FGFR3 inhibitor being studied at low doses to modulate overactive FGFR3 signaling in children with achondroplasia; Phase 3 registrational trial initiated (PROPEL 3).
BBP-812
Investigational AAV9 gene therapy program intended to deliver functional copies of the ASPA gene for treatment of Canavan disease; in Phase 2 development.
Patidegib topical gel
Topically administered hedgehog-pathway inhibitor formulated to limit systemic exposure for treatment of Gorlin syndrome–associated frequent basal cell carcinoma; in Phase 3 clinical development.
Attruby (acoramidis)
Commercial prescription small-molecule therapy indicated for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) to reduce death and cardiovascular-related hospitalizations.
Encaleret
Investigational orally administered small-molecule negative allosteric modulator of the calcium-sensing receptor being developed to restore mineral homeostasis in disorders characterized by CASR gain-of-function (including ADH1); being evaluated in global Phase 3 studies.
BBP-418
Investigational oral small molecule intended to increase glycosylation of alpha-dystroglycan by saturating partially functional FKRP enzyme activity, developed for limb-girdle muscular dystrophy type 2I/R9; in Phase 3 development.
Low-dose infigratinib (achondroplasia program)
Oral small-molecule FGFR3 inhibitor being studied at low doses to modulate overactive FGFR3 signaling in children with achondroplasia; Phase 3 registrational trial initiated (PROPEL 3).
BBP-812
Investigational AAV9 gene therapy program intended to deliver functional copies of the ASPA gene for treatment of Canavan disease; in Phase 2 development.
Patidegib topical gel
Topically administered hedgehog-pathway inhibitor formulated to limit systemic exposure for treatment of Gorlin syndrome–associated frequent basal cell carcinoma; in Phase 3 clinical development.
Attruby (acoramidis)
Commercial prescription small-molecule therapy indicated for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) to reduce death and cardiovascular-related hospitalizations.
Services
Licensing and partnership collaborations
Negotiation and management of research collaborations, licensing agreements, and portfolio divestments with academic and industry partners.
No-charge genetic testing and counseling program
Provision of sponsored genetic testing and counseling programs targeting genes associated with specific genetic conditions to identify eligible patients for research and clinical programs.
Expanded access request evaluation
Case-by-case assessment of pre-approval investigational drug access requests, including benefit-risk review, IRB requirement verification, and supply considerations.
Licensing and partnership collaborations
Negotiation and management of research collaborations, licensing agreements, and portfolio divestments with academic and industry partners.
No-charge genetic testing and counseling program
Provision of sponsored genetic testing and counseling programs targeting genes associated with specific genetic conditions to identify eligible patients for research and clinical programs.
Expanded access request evaluation
Case-by-case assessment of pre-approval investigational drug access requests, including benefit-risk review, IRB requirement verification, and supply considerations.
Expertise Areas
- Clinical trial management
- Small-molecule drug development
- AAV gene therapy development
- Genetic-disease target discovery
Key Technologies
- Small-molecule therapeutics
- Adeno-associated virus (AAV) gene delivery
- Allosteric receptor modulation
- FGFR inhibition